Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025)
Inhibrx Biosciences (INBX) reported Depreciation & Amortization (CF) of $564000.0 for Q4 2025, down 18.14% year-over-year from $689000.0 in Q4 2024, and down 3.09% quarter-over-quarter from $582000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $564000.0 in Q4 2025.
- Depreciation & Amortization (CF) for Q4 2025 came in at $564000.0, down 18.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.5 million (up 8.71% YoY), and the FY2025 annual result was $2.5 million, up 8.67% from the prior year.
- Depreciation & Amortization (CF) retreated to $564000.0 in Q4 2025 per INBX's latest filing, from $582000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $760000.0 in Q3 2024 and troughed at $295000.0 in Q2 2023.
- A 3-year average of $514909.1 and a median of $564000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 150.0% in 2024, then fell 23.42% in 2025.
- A 3-year view of Depreciation & Amortization (CF) shows it stood at $298000.0 in 2023, then soared by 131.21% to $689000.0 in 2024, then dropped by 18.14% to $564000.0 in 2025.
- Business Quant data shows INBX's Depreciation & Amortization (CF) at $564000.0 in Q4 2025, $582000.0 in Q3 2025, and $662000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | 564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 564,000.00 |
| Dec 31, 2025 | 564,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 675,000.00 |
| Mar 31, 2025 | 675,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 304,000.00 |
| Sep 30, 2023 | 304,000.00 |